Related by context. All words. (Click for frequent words.) 72 elotuzumab 71 dacetuzumab 71 forodesine 71 ruxolitinib 70 phase IIb clinical 70 tanespimycin 70 phase IIb trial 70 ZOLINZA 70 lumiliximab 70 ganetespib 70 alvespimycin 69 enzastaurin 69 MAGE A3 ASCI 69 vemurafenib 69 oral ridaforolimus 69 iclaprim 69 pomalidomide 68 AP# [003] 68 HGS# 68 NP2 Enkephalin 68 BRAF inhibitor 68 YONDELIS 68 brivaracetam 68 neratinib 68 dalbavancin 68 INCB# [001] 68 tezampanel 68 ixabepilone 68 Allovectin 7 68 BAY #-# 68 PXD# 67 teriflunomide 67 Phase Ib study 67 Cimzia TM 67 axitinib 67 Traficet EN 67 OHR/AVR# 67 registrational 67 UPLYSO 67 OMAPRO 67 CIMZIA TM 67 talactoferrin 67 obatoclax 67 Phenoptin 67 IMA# 67 oral methylnaltrexone 67 HuLuc# 67 phase IIa clinical 67 nilotinib 67 Amigal 67 Tarceva TM 67 bicifadine 67 RSR# 67 EVIZON 67 oral prodrug 67 Bezielle 67 crizotinib PF # 67 midstage studies 67 OvaRex ® MAb 67 Onrigin 67 TELCYTA 67 JAK inhibitor 67 amrubicin 67 Azedra 67 Insegia 66 lupus nephritis 66 pralatrexate 66 TOLAMBA 66 MyVax 66 refractory CLL 66 lintuzumab 66 romidepsin 66 ToGA 66 Revlimid lenalidomide 66 severe hypercholesterolemia 66 receptor tyrosine kinase inhibitor 66 sapacitabine 66 Zemplar Capsules 66 ALGRX 66 Cloretazine 66 dose cohort 66 INCB# [002] 66 riociguat 66 Phase #b/#a 66 Symadex 66 gastrointestinal stromal tumors GIST 66 IL# PE#QQR 66 indolent NHL 66 HuMax CD4 66 vosaroxin 66 PEG PAL 66 Corlux 66 RSD# oral 66 vidofludimus 66 vandetanib 66 Bicifadine 66 trastuzumab DM1 T DM1 66 Velcade bortezomib 66 Sym# 66 heavily pretreated 66 Aurexis 66 Dacogen injection 66 Xanafide 66 HCD# [002] 66 SinuNase 66 HGS ETR2 65 heterozygous FH 65 PEG SN# 65 BLA filing 65 ACTEMRA TM 65 INC# 65 dose cohorts 65 ELACYT 65 deforolimus 65 Allovectin 7 ® 65 docetaxel Taxotere ® 65 zalutumumab 65 aflibercept 65 lomitapide 65 Jevtana 65 Firazyr 65 CoFactor 65 motesanib 65 relapsed refractory multiple myeloma 65 Zenvia ™ 65 Panzem R NCD 65 regorafenib 65 anidulafungin 65 CINTREDEKIN BESUDOTOX 65 anti angiogenic agents 65 faropenem 65 lesinurad 65 APTIVUS 65 Quinamed 65 relapsed MCL 65 docetaxel Taxotere R 65 TREANDA 65 histone deacetylase HDAC inhibitor 65 Amrubicin 65 CIMZIA TM certolizumab pegol 65 Targretin 65 MGd 65 TYZEKA 65 cell lymphoma CTCL 65 registrational trial 65 sunitinib malate 65 mapatumumab 65 alvimopan 65 NVA# 65 ZYBRESTAT 65 L MTP PE 65 phase IIb study 65 MyVax R 65 Pixuvri 65 cediranib 65 dasatinib 65 Civacir 65 belinostat 65 G#DT 65 TELINTRA 65 FOLOTYN ® 65 PDE# inhibitors 65 cannabinor 65 OMNARIS HFA 65 atrasentan 65 Icatibant 65 SNT MC# 65 HuMax EGFr 65 GAMMAGARD 65 relapsed multiple myeloma 65 BCR ABL inhibitors 65 ProSavin 65 FOLOTYN 65 Ophena TM 65 Aptivus ® 65 Ceflatonin 65 Fodosine 65 tecarfarin 65 JAK2 inhibitor 65 briakinumab 65 Phase 2a trial 65 LEUKINE 65 ularitide 65 OPAXIO 65 virus HCV protease inhibitor 65 CR# vcMMAE 65 EndoTAG TM -1 65 cilengitide 65 Nasulin 65 Gleevec imatinib 65 lymphoma CTCL 65 Cinquil 65 Zybrestat 65 Phase #/#a trial 65 EOquin 65 GSK# [001] 65 eltrombopag 65 Pimavanserin 65 APTIVUS r 65 ocrelizumab 65 recurrent glioblastoma multiforme 65 methylnaltrexone 65 SAR# [004] 65 Carfilzomib 65 atacicept 65 diabetic neuropathic pain 64 elvucitabine 64 Zolinza 64 JNJ Q2 64 liprotamase 64 #D#C# 64 visilizumab 64 OncoVEX GM CSF 64 Tyrima 64 OncoVEX 64 opioid induced bowel dysfunction 64 BrachySil TM 64 relapsing remitting multiple sclerosis 64 MabCampath 64 oxymorphone ER 64 IRX 2 64 hour bronchodilation 64 Prestara 64 liposomal formulation 64 pertuzumab 64 eosinophilic asthma 64 LibiGel ® 64 pazopanib 64 SPRYCEL ® 64 INT# [002] 64 ARIKACE ™ 64 RAPTIVA 64 tezampanel NGX# 64 Ambrisentan 64 investigational therapies 64 SUCCEED trial 64 SUTENT 64 tivozanib 64 panitumumab Vectibix 64 evaluating tivozanib 64 IMC A# 64 otelixizumab 64 adipiplon 64 Virulizin ® 64 Cimzia ® certolizumab pegol 64 acyclovir Lauriad R 64 investigational humanized monoclonal antibody 64 EOquin TM 64 refractory AML 64 imatinib mesylate Gleevec 64 metastatic CRC 64 trabectedin 64 rituximab Rituxan 64 phase IIa 64 lintuzumab SGN 64 casopitant 64 RGB # 64 MAA submission 64 Sutent sunitinib 64 tafamidis 64 TLK# 64 ridaforolimus 64 apremilast 64 CCR5 antagonist 64 NATRECOR ® 64 BENLYSTA ® 64 Benlysta belimumab 64 gefitinib Iressa 64 bortezomib Velcade 64 LymphoStat B 64 sorafenib Nexavar 64 rNAPc2 64 Diamyd ® 64 dasatinib Sprycel 64 Romidepsin 64 myelofibrosis 64 mipomersen 64 CANCIDAS 64 sorafenib tablets 64 glufosfamide 64 adalimumab Humira 64 dirucotide 64 Vilazodone 64 LAF# 64 anticancer compound 64 Phase IIIb clinical 64 favorable tolerability 64 EFAPROXYN 64 DACH platinum 64 torezolid phosphate 64 Viramidine 64 phase IIb 64 thalidomide Thalomid 64 Plicera 64 ofatumumab 64 SCH # 64 placebo controlled clinical trials 64 CYT# 64 bendamustine 64 proteasome inhibitor 64 Stedivaze 64 Treanda 64 EGFR inhibitors 64 Targretin capsules 64 confirmatory clinical 64 BRIM2 64 FOLFIRINOX 64 HGS ETR1 64 peginesatide 64 BLA submission 64 AAG geldanamycin analog 64 Phase 2b clinical 64 anti leukemic 64 favorable pharmacokinetic profile 64 tocilizumab 64 ISTODAX 64 Doxil ® 64 VITAL Trial 64 eniluracil 64 lapatinib Tykerb 64 Vandetanib 64 rALLy trial 64 radezolid 64 efalizumab 64 hoFH 64 XmAb# 64 bazedoxifene 64 Panzem 64 lasofoxifene 64 Phase #b/#a clinical 64 tipranavir 64 FIRMAGON R 64 cetuximab Erbitux ® 64 ADVEXIN 64 Arikace 64 Octreolin 64 PRT# 64 Dalbavancin 64 NEBIDO 64 subcutaneous formulation 64 ruboxistaurin 64 MOZOBIL 64 Romiplostim 64 LHRH antagonists 64 TOCOSOL Paclitaxel 64 Ixempra 64 canakinumab 63 MGCD# [001] 63 PDE4 inhibitor 63 ongoing Phase 1b 63 cutaneous T cell 63 Actilon 63 imatinib resistant 63 anthracyclines taxanes 63 HoFH 63 Phase IIa trials 63 paliperidone ER 63 PANVAC VF 63 dosage regimens 63 rhThrombin 63 JAK inhibitors 63 gemifloxacin 63 galiximab 63 pan HDAC inhibitor 63 AGILECT R 63 volociximab 63 custirsen 63 Abatacept 63 CIMZIA ™ 63 Leukine 63 antiangiogenic therapy 63 decitabine 63 IAP inhibitors 63 Telintra 63 Fludara 63 Allovectin 7 R 63 ARCOXIA 63 MYLOTARG 63 Fludara ® 63 THALOMID 63 PREOS 63 huC# DM4 63 orBec 63 TBC# 63 elacytarabine 63 LymphoStat B TM 63 non metastatic osteosarcoma 63 TG# [003] 63 ASSERT trial 63 oral rivaroxaban 63 Gleevec Glivec 63 GRN# 63 cetuximab Erbitux 63 sNDA submission 63 budesonide foam 63 Phase 1a clinical 63 iniparib 63 APTIVUS R 63 Zelrix 63 Evoltra 63 docetaxel Taxotere 63 Troxatyl 63 Aflibercept 63 standard chemotherapy regimen 63 abatacept 63 ARIKACE 63 Phase IIb clinical trials 63 DermaVir Patch 63 TACI Ig 63 DASISION 63 IMGN# 63 Cladribine Tablets 63 PRTX 63 L BLP# 63 Omigard 63 bosutinib 63 entinostat 63 NATRECOR R 63 Phase IIB 63 orally administered inhibitor 63 Bronchitol 63 sargramostim 63 BAL# [002] 63 refractory Hodgkin lymphoma 63 palifosfamide 63 AZILECT ® 63 Personalized Immunotherapy 63 tolevamer 63 CDP# 63 sipuleucel T 63 HQK 63 Soliris TM eculizumab 63 Catena ® 63 assessing T DM1 63 Tekamlo 63 telbivudine 63 cangrelor 63 Pafuramidine 63 reslizumab 63 CUSTOM III 63 Mipomersen 63 MEND CABG II 63 Elagolix 63 refractory gout 63 Vectibix panitumumab 63 Phase IIb trials 63 paclitaxel Taxol ® 63 Genentech Roche 63 Panzem R 63 AEGR 63 Plenaxis TM 63 alefacept 63 MEK inhibitors 63 selective modulator 63 trastuzumab DM1 63 BNC# 63 CTAP# Capsules 63 ICA # 63 celgosivir 63 Aplidin 63 DAVANAT 63 valopicitabine 63 refractory multiple myeloma 63 interferon beta therapy 63 R#/MEM # 63 AeroLEF TM 63 octreotide implant 63 XL# XL# 63 Evoltra ® 63 Sebivo 63 pegfilgrastim 63 ONTAK 63 velafermin 63 delafloxacin 63 metastatic sarcomas 63 Nuvion 63 posaconazole 63 Telatinib 63 Pemetrexed 63 biologic therapy 63 Orathecin 63 relapsed MM 63 S/GSK# 63 SinuNase TM 63 HuMax CD# 63 mg/m2 cohort 63 antibody MAb 63 Phase 2b study 63 immunomodulatory therapy 63 AZILECT R 63 Asentar 63 placebo controlled Phase 63 varespladib 63 dose escalation phase 63 teduglutide 63 refractory chronic lymphocytic 63 torezolid 63 viral kinetics 63 aclidinium 63 recurrent GBM 63 REMICADE ® 63 PRIMO CABG 63 Chemophase 63 ENMD # 63 Advexin 63 maribavir 63 Ocrelizumab 63 StaphVAX 63 erlotinib Tarceva 63 VEGF inhibitors 63 MGN# 63 fluvastatin 63 LY# [003] 63 DPP4 63 Reverset 63 GRN#L 63 Restanza 63 recurrent glioblastoma 63 rALLy clinical trial 63 GALNS 63 Zenvia Phase III 63 CBLC# 63 cetuximab Erbitux R 63 farletuzumab 63 randomized Phase 2b 63 randomized Phase IIb 63 LEP ETU 63 chronic angina 63 metastatic HRPC 63 Rhucin R 63 Advagraf 63 Rhucin ® 63 oxypurinol 62 MKC# MT 62 AEG# 62 relapsed SCLC 62 Gleevec imatinib mesylate 62 carfilzomib 62 FTY# 62 PLX# 62 HCV protease inhibitor 62 cutaneous T 62 TYSABRI natalizumab 62 baminercept 62 TroVax ® 62 dexanabinol 62 CA4P 62 rilonacept 62 zanolimumab 62 KIACTA ™ 62 Maribavir 62 erlotinib Tarceva ® 62 midstage clinical 62 systemic ALCL 62 INTEGRILIN 62 Increlex ® 62 Tocosol Paclitaxel 62 docetaxel chemotherapy 62 Archexin 62 Seliciclib 62 pediatric acute lymphoblastic 62 TriRima 62 Phase 1b trial 62 hypereosinophilic syndrome 62 dasatinib Sprycel ® 62 daclizumab 62 Evoltra TM 62 PROMACTA 62 Nexavar sorafenib 62 INTERCEPT platelets 62 multi kinase inhibitor 62 double blinded placebo 62 acyclovir Lauriad ® 62 ALN TTR 62 Xcytrin 62 tremelimumab 62 Dasatinib 62 afamelanotide 62 CCX# 62 LUMINATE 62 PROVENGE sipuleucel T 62 Telavancin 62 Raptiva ® 62 dimebon 62 Betaferon ® 62 splenectomized patients 62 INDs 62 Gleevec resistant 62 Clolar 62 MACUGEN 62 phase Ib 62 prGCD 62 desvenlafaxine 62 bortezomib Velcade R 62 radiation sensitizer 62 Folotyn 62 chlorambucil 62 synthetic retinoid 62 tramiprosate Alzhemed TM 62 rindopepimut 62 Triapine 62 AVASTIN 62 GSK# [002] 62 mRCC 62 ISENTRESS 62 Omacetaxine 62 Fibrillex TM 62 Zarnestra 62 phase 2a 62 confirmatory Phase III 62 Mepact 62 ALVESCO HFA 62 Ereska 62 TNF alpha inhibitor 62 hematological cancers 62 ATPace TM 62 Clolar ® 62 ISIS # 62 CORT # 62 cancer immunotherapies 62 KRN# 62 Urocortin 2 62 Xcytrin R 62 BRIM3 62 CytoFabTM 62 Tavocept 62 Huntexil 62 omacetaxine 62 doripenem 62 PHX# 62 subcutaneously administered 62 ACZ# 62 superficial bladder cancer 62 SUTENT ® 62 BYDUREON 62 Onco TCS 62 achieved sustained virological 62 EndoTAGTM 1 62 Proquin XR 62 FROVA 62 Actimmune ® 62 nucleoside analogs 62 bardoxolone 62 PS# [001] 62 FavId 62 glatiramer acetate 62 ORENCIA ® 62 CD# antibody [001] 62 Vernakalant 62 Telbivudine 62 CLORETAZINE TM VNP#M 62 non nucleoside HCV 62 Noxafil 62 Nebido 62 TORISEL 62 mycophenolate mofetil 62 interferon gamma 1b 62 vismodegib 62 NUVIGIL 62 nab paclitaxel 62 imatinib Gleevec 62 SPARLON 62 Nexavar ® 62 metaglidasen 62 Fibrin Pad 62 muraglitazar 62 Xinlay 62 perampanel 62 Sprycel dasatinib 62 Phase #/#a 62 COMFORT II 62 Hedgehog antagonist 62 Pazopanib 62 Ventavis 62 tyrosine kinase inhibitor 62 lenalidomide dexamethasone 62 Theratope 62 HspE7 62 tubulin inhibitor 62 DU #b 62 durable remissions 62 eritoran 62 Laquinimod 62 aleglitazar 62 treprostinil 62 oral taxane 62 PRX # 62 Kynapid 62 RoACTEMRA 62 GEM OS2 62 CYT# potent vascular disrupting 62 complete cytogenetic response 62 JAK1 62 corticosteroid dexamethasone 62 MERLIN TIMI 62 oral FTY# 62 Genz # 62 SLx 62 Telaprevir 62 successfully commercialize Iluvien 62 Proxinium TM 62 heavily pretreated patients 62 HCV protease inhibitors 62 platinum refractory 62 Herceptin trastuzumab 62 myeloproliferative disorders 62 mertansine 62 esophageal candidiasis 62 GEM OS1 62 romiplostim 62 Campath alemtuzumab 62 Cleviprex TM clevidipine 62 Neulasta ® 62 SARMs 62 temsirolimus 62 Phase Ib clinical 62 ProLindac 62 uric acid lowering 62 RIGScan CR 62 MabThera Rituxan 62 crizotinib 62 Zalbin 62 BCR ABL inhibitor 62 therapeutic regimens 62 MoxDuo IR 62 Amplimexon 62 rFVIIa 62 infusional 5-FU/LV 62 initiate Phase 1b 62 PEGylated interferon beta 1a 62 Zingo TM 62 Zenvia TM 62 Phase Ib II 62 CRMD# 62 selective S#P# receptor agonist 62 methylnaltrexone tablet 62 IRESSA 62 Apoptone 62 metastatic renal cell 62 placebo controlled clinical 62 PrevOnco 62 Lixivaptan 62 SILENOR 62 PNP inhibitor 62 budiodarone 62 RG# [001] 62 certolizumab 62 Veronate 62 midstage trials 62 systemic anaplastic large 62 Revimmune 62 relapsing MS 62 Altastaph 62 evaluating REVLIMID 62 imatinib therapy 62 Annamycin 62 Interferon alpha 62 CEQ# 62 ACTEMRA 62 Ketotransdel 62 pegylated interferons 62 Dendreon Provenge 62 TREDAPTIVE 61 bucindolol 61 TRISENOX 61 TLR8 agonist 61 GLYX 61 XL# XL# XL# XL# 61 ofatumumab HuMax CD# 61 Onconase 61 odanacatib 61 OvaRex R 61 Alzhemed TM 61 bevacizumab Avastin ® 61 Lialda 61 Vidaza azacitidine 61 drug ISA# 61 Marqibo 61 Manja Bouman CEO 61 Azixa 61 Abiraterone acetate 61 YERVOY 61 AzaSite Plus 61 VAPRISOL 61 caspofungin 61 ANCHOR trial 61 vascular disrupting agent 61 ORENCIA R 61 catheter occlusion 61 darapladib 61 NGX# 61 IPL# 61 lurasidone 61 PROSTVAC TM 61 T DM1 61 Dextofisopam 61 PRECiSE 61 Junovan 61 IMC #B 61 indiplon capsules 61 Santhera 61 Tykerb lapatinib 61 ribavirin RBV 61 Triapine R 61 vorinostat 61 VA# [002] 61 Northera 61 fidaxomicin 61 brentuximab vedotin SGN 61 SinuNase ™ 61 Stelara 61 Anavex #-# 61 Canvaxin TM 61 Triolex 61 cystinosis patients 61 Taxotere ® 61 Vfend 61 oxaliplatin Eloxatin 61 abiraterone acetate 61 evaluable subjects 61 ADAGIO study 61 INCB# [003] 61 metastatic hormone refractory 61 dextromethorphan quinidine 61 balsalazide tablet 61 AMN# [001] 61 omacetaxine mepesuccinate 61 ezogabine 61 Pivotal Phase III 61 QVA# 61 ON #.Na 61 azficel T 61 OXi# 61 HERCEPTIN 61 telaprevir VX 61 Neulasta R 61 entecavir 61 PRECISE trial 61 verteporfin 61 ticagrelor Brilinta 61 lucinactant 61 blinatumomab 61 pradefovir 61 IIa trial 61 Study GL# 61 ceftaroline 61 efficacy tolerability 61 BCX# 61 Linjeta TM 61 secondary efficacy endpoints 61 DDP# 61 Tasimelteon 61 REMINYL ® 61 Certican 61 Phase IIa clinical trials 61 Diovan HCT 61 NXL# 61 pegylated interferon alpha 61 #I TM# 61 Deforolimus 61 SPIRIVA HandiHaler 61 Cethromycin 61 cabazitaxel 61 omega interferon 61 Zytiga 61 Lacosamide 61 oral salmon calcitonin 61 clinical pharmacology studies 61 perifosine 61 pemphigus vulgaris 61 Orazol 61 DAPT 61 DR Cysteamine 61 intranasal formulation 61 Golimumab 61 T#I [002] 61 Ostarine 61 IMiDs 61 metastatic renal cell carcinoma 61 RRMS patients 61 panitumumab 61 Pirfenidone 61 ONCONASE R 61 NEUVENGE 61 TAXOTERE ® 61 novel oral anticoagulant 61 mTOR inhibitor 61 TransVax TM 61 liposomal doxorubicin 61 Arranon 61 TKI therapy 61 ImClone Erbitux 61 Q#IR 61 REG1 61 HEPLISAV 61 complete remissions 61 lorvotuzumab mertansine 61 JANUVIA 61 ZACTIMA 61 surrogate endpoint 61 relapsed ovarian cancer 61 oral deforolimus 61 angiogenesis inhibitor 61 vilazodone 61 imatinib Gleevec ® 61 subcutaneous PRO 61 Nanobody 61 Rebif ® 61 Hepatocellular Carcinoma HCC 61 BR.# 61 dosing cohort 61 Pertuzumab 61 bortezomib refractory 61 huN# DM1 61 PDX pralatrexate 61 generation purine nucleoside 61 Tamibarotene 61 investigational monoclonal antibody 61 MAXY alpha 61 oritavancin 61 vinflunine 61 MyVax personalized immunotherapy 61 ATL/TV# 61 Phase IIa trial 61 Serada 61 XL# [003] 61 etravirine 61 dosing cohorts 61 pitavastatin 61 nonclinical studies 61 ThermoDox R 61 Technosphere Insulin 61 Zerenex 61 lacosamide 61 KRAS mutations occur 61 Phase 2a clinical trials 61 Akt inhibitor 61 Arcalyst 61 imatinib mesylate 61 MNTX 61 brentuximab 61 investigational antiplatelet agent 61 ROTATEQ 61 ALKS 61 daptomycin 61 EDEMA3 61 abiraterone 61 MEK inhibitor 61 Octreotide 61 HER2 positive metastatic breast 61 noninfectious uveitis 61 ILLUMINATE 61 Sudhir Agrawal D.Phil 61 efficacy endpoint 61 Dificid 61 diabetic gastroparesis 61 refractory PTCL 61 ACAPODENE 61 venlafaxine ER 61 sNDA filing 61 targeted radiotherapeutic 61 elesclomol 61 CRx 61 Hycamtin 61 ATL# [001] 61 CAELYX 61 pivotal bioequivalence 61 Phase IIa clinical 61 standard chemotherapy regimens 61 clinicaltrials 61 PI3K/Akt pathway inhibitor 61 BARACLUDE ® 61 Dyloject TM 61 pemetrexed Alimta 61 JZP 61 fosbretabulin 61 Erbitux cetuximab 61 Increlex R 61 Vascugel 61 pancreatic neuroendocrine tumors 61 ASONEP 61 TPI ASM8 61 Azilect ® 61 SCIg 61 rasagiline tablets 61 brentuximab vedotin 61 Phase Ib 61 Dapagliflozin 61 cancer neuroendocrine tumor 61 adecatumumab MT# 61 DCCR 61 acetonide FA 61 tigecycline 61 ADVEXIN clinical 61 viral kinetic 61 INTELENCE 61 Solazed 61 KAPVAY ™ 61 TNF alpha inhibitors